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Abstract: Succinate dehydrogenase (SDH)-deficient renal carci-
noma has been accepted as a provisional entity in the 2013 In-
ternational Society of Urological Pathology Vancouver
Classification. To further define its morphologic and clinical
features, we studied a multi-institutional cohort of 36 SDH-
deficient renal carcinomas from 27 patients, including 21 pre-
viously unreported cases. We estimate that 0.05% to 0.2% of all
renal carcinomas are SDH deficient. Mean patient age at pre-
sentation was 37 years (range, 14 to 76 y), with a slight male
predominance (M:F=1.7:1). Bilateral tumors were observed in
26% of patients. Thirty-four (94%) tumors demonstrated the
previously reported morphology at least focally, which included:
solid or focally cystic growth, uniform cytology with eosino-
philic flocculent cytoplasm, intracytoplasmic vacuolations and
inclusions, and round to oval low-grade nuclei. All 17 patients
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who underwent genetic testing for mutation in the SDH sub-
units demonstrated germline mutations (16 in SDHB and 1 in
SDHC). Nine of 27 (33%) patients developed metastatic disease,
2 of them after prolonged follow-up (5.5 and 30 y). Seven of 10
patients (70%) with high-grade nuclei metastasized as did all 4
patients with coagulative necrosis. Two of 17 (12%) patients
with low-grade nuclei metastasized, and both had unbiopsied
contralateral tumors, which may have been the origin of the
metastatic disease. In conclusion, SDH-deficient renal carcino-
ma is a rare and unique type of renal carcinoma, exhibiting
stereotypical morphologic features in the great majority of cases
and showing a strong relationship with SDH germline mutation.
Although this tumor may undergo dedifferentiation and meta-
stasize, sometimes after a prolonged delay, metastatic disease is
rare in the absence of high-grade nuclear atypia or coagulative
necrosis.
Key Words: SDHB, SDHA, succinate dehydrogenase, renal
carcinoma
(Am J Surg Pathol 2014;38:1588–1602)
Loss of immunohistochemical (IHC) staining for succi-nate dehydrogenase subunit B (SDHB) has been
consistently demonstrated in pheochromocytomas/para-
gangliomas, gastrointestinal stromal tumors (GISTs), renal
carcinomas, and pituitary adenomas arising in the setting of
germline mutation of SDHA, SDHB, SDHC, SDHD, and
SDHAF2.1–17 Tumors that show loss of staining for SDHB
(indicating disruption of the mitochondrial complex 2 for
any reason, not just SDHB mutation) have been termed
succinate dehydrogenase (SDH) deficient.1 In addition to
absent staining for SDHB, tumors associated with SDHA
mutation also show loss of staining for SDHA, whereas
tumors associated with germline mutation of SDHB,
SDHC, SDHD, and SDHAF2 show positive staining for
SDHA.1,13,15,18–20
Because of their strong syndromic and hereditary
basis and distinct natural history, SDH-deficient tumors are
important to recognize.1 To date, 53 patients with renal
neoplasms arising in the setting of germline SDH mutation
have been reported (summarized in Supplementary Table 1,
Supplemental Digital Content 1, http://links.lww.com/
PAS/A224).4,16,17,21–42 Briefly, 41 cases have been reported
arising in the setting of SDHB mutation, 5 in the setting of
SDHC mutation, 3 in the setting of SDHD mutation, and
none in the setting of SDHA mutation. In 4 cases loss of
IHC staining for SDHB has been reported without follow-
up SDH mutation testing, but all patients with SDH-defi-
cient renal carcinoma who have undergone complete ge-
netic testing to date have been shown to have germline
mutation in one of the SDH subunits.
In 2010, we reported that renal carcinomas occur-
ring secondary to SDH mutation can be identified by loss
of IHC staining for SDHB.12 In 2011, we reported that
SDH-deficient renal carcinomas demonstrate distinctive
features that allow them to be recognized prospectively
and that this morphology can be used to triage IHC
staining for SDHB as a prelude to formal genetic testing.4
Subsequently SDH-deficient renal carcinoma has been
recognized as a provisional entity in the recently pub-
lished 2013 International Society of Urological Pathology
(ISUP) Vancouver Classification of renal tumors.43 The
entity holds provisional status because relatively few cases
have been reported, and therefore experience with the
morphologic, immunohistochemical, and clinical fea-
tures, including long-term outcome, has been limited.
We therefore initiated a broad international col-
laboration to study these tumors, with the following aims:
(1) To identify new cases of SDH-deficient renal carci-
noma to further expand knowledge and experience
with these carcinomas.
(2) To enable a centralized pathologic review of
previously published cases of SDH-deficient renal
carcinoma.
(3) To establish the natural history, clinical features, and
prognosis of SDH-deficient renal carcinoma.
(4) To establish the risk of germline SDH mutation
associated with SDH-deficient renal carcinoma.
(5) To estimate the incidence of SDH-deficient renal
carcinoma.
METHODS
Case Retrieval and Review
Surgical pathologists with subspecialty interest in
urologic pathology or in the pathology of SDH-deficient
tumors from 15 institutions in North America, Europe,
Asia, and Australia were contacted to submit cases of
renal carcinoma occurring in the setting of proven SDH
mutation or cases suspected to be associated with SDH
deficiency on the basis of morphology, IHC, or a personal
or family history of paragangliomas or SDH-deficient
GIST. Pathologists were provided with detailed morpho-
logic descriptions, photomicrographs, and published pa-
pers,4,12 summarizing the previously reported morphology
of SDH-deficient renal carcinomas and were asked to re-
view their files for any cases with compatible morphology.
Pathologists were asked to provide either a representative
block or 10 to 15 unstained slides for centralized pathol-
ogy review, IHC, and/or genetic testing. Cases from pa-
tients previously reported in any form (patients 41 to 53 in
Supplementary Table 1, Supplemental Digital Content 1,
http://links.lww.com/PAS/A224) were also included for
review if slides were available, but they were recorded
separately to prevent confusion due to double publication
of data. For previously published cases, the originating
collaborators provided additional clinical follow-up in-
formation if available. All submitted cases underwent
centralized pathologic review. If the original hematoxylin
and eosin sections were unavailable for review (3 cases),
the morphologic review was performed by telepathology
on scanned whole-slide sections.
Immunohistochemistry
Cases with proven SDH mutation or with compat-
ible morphology underwent IHC analysis for SDHB and
SDHA, which was performed on whole sections with
Am J Surg Pathol  Volume 38, Number 12, December 2014 SDH-deficient Renal Carcinoma
r 2014 Lippincott Williams & Wilkins www.ajsp.com | 1589
mouse monoclonal antibodies against SDHB (ABCAM
ab14714, clone 21A11, dilution 1 in 100) and SDHA
(Mitosciences Abcam MS204, clone 2E, dilution of 1 in
1000), -detailed methods previously described.3,4,6,12,13,15,18
Cases with definite granular cytoplasmic staining were
classified as SDHB/SDHA positive. Cases with absent
cytoplasmic staining in the presence of an internal positive
control of non-neoplastic cells were classified as negative.
If there was negative staining in the neoplastic cells but no
internal positive control in the non-neoplastic cells, the
staining was considered indeterminate and repeated. A
panel of IHC markers commonly used in urologic path-
ology (PAX8, AMACR, CD10, c-KIT, AE1/AE3, CK8/
18, cytokeratin 7, cytokeratin 20, and EMA) was also
performed if tissue was available.
Molecular Methods
DNA Extraction
DNA from formalin-fixed paraffin-embedded
(FFPE) tumor tissue was extracted using QIAsymphony
DNA Mini Kit (Qiagen, Hilden, Germany) on an auto-
mated extraction system (QIAsymphony SP; Qiagen) ac-
cording to manufacturer’s supplementary protocol for
FFPE samples (Purification of genomic DNA from FFPE
tissue using the QIAamp DNA FFPE Tissue Kit and
Deparaffinization Solution). Concentration and purity of
isolated DNA was measured using NanoDrop ND-1000
(NanoDrop Technologies Inc., Wilmington, DE). DNA
integrity was examined by amplification of control genes
in a multiplex polymerase chain reaction (PCR).
Analysis of SDHB Gene Mutation
Mutational analysis of complete CDS and exon-in-
tron junctions of the SDHB gene was performed using PCR
and direct sequencing. Briefly, 100ng DNA was added to a
reaction mixture consisting of 12.5mL of FastStart PCR
Master (Roche Diagnostic, Mannheim, Germany), 10pmol
of forward and reverse primers, and distilled water up to
25mL. The amplification program consisted of denaturation
at 951C for 9 minutes, 35 cycles of denaturation at 951C for
1 minute, annealing 621C for 1 minute, and extension at
721C for 1 minute. The program was terminated by in-
cubation at 721C for 7 minutes. The PCR products were
separated by electrophoresis through a 2% agarose gel.
Successfully amplified PCR products selected for
sequencing analysis were purified with magnetic particles
Agencourt AMPure (Agencourt Bioscience Corporation,
A Beckman Coulter Company; Beverly, MA), both side
sequenced using Big Dye Terminator Sequencing kit
(Applied Biosystems) and purified with magnetic particles
Agencourt CleanSEQ (Agencourt Bioscince Corporation,
A Beckman Coulter Company), all according to the
TABLE 1. Clinical, Pathologic, and IHC Features of Previously Unreported SDH-deficient Renal Carcinomas
Location Age Sex
Size
(mm) Surgery Stage
ISUP
Grade Necrosis Status
Follow-up
(mo)
1 Right 35 M 75 Partial nephrectomy 2 (T2AN0) 2 No ANED 3
2 Left 76 F 25 Partial nephrectomy 1 (T1AN0) 2 No ANED 0
3 Right 32 F 68 Nephrectomy 1 (T1BN0) 2 No ANED 8
4 M ANED
Right 34 50 Wedge 1 (T1BN0) 2 No ANED 53
Left 35 75 Nephrectomy 2 (T2AN0) 4w No ANED 50
Left 35 47 Nephrectomy 1 (T1BN0) 2 No ANED 50
Left 35 40 Nephrectomy 1 (T1AN0) 2 No ANED 50
5 M
Left 45 50 Nephrectomy 1 (T1BN0) 2 No ANED 27
Left 45 41 Nephrectomy 1 (T1BN0) 2 No ANED 27
Right 45 7 Wedge 1 (T1AN0) 2 No ANED 25
6 Left 43 F 38 Nephrectomy 1 (T1AN0) 2 No ANED 38
7 Right 31 F 35 Partial nephrectomy 1 (T1AN0) 2 No ANED 1
8 Right 16 M 45 Nephrectomy 1 (T1BN0) 2 No ANED 1
9 Right 46 M 85 Nephrectomy 3 No ANED 4
10 Right 30 F 90 Nephrectomy (left kidney mass
found, 362mo not resected)
p2 (T2AN0) 2 No AWD vertebral
met 362mo
368z
11* M
Left 14 2 No AUNDS 240
Right 18 2 No AUNDS 192
Right 18 2 No AUNDS 192
12* ? 44 F 4w Yes DOD 12
13 Right 57 M 60 Partial nephrectomy (left kidney
70mm mass unresected)
p3 (T3aN0) 2 No DOD Liver
met 4mo
10
14 Right 54 M 28 Partial nephrectomy 1 (T1aN0) 2 No ANED 5
*Case 12 is the mother of case 11.
wTumor showed areas of high-grade transformation in direct continuity with lower-grade areas.
zAt the time of presentation with metastatic disease the patient was found to have a metachronous tumor in the left kidney (not biopsied). Therefore the vertebral
metastasis may represent either a delayed metastasis from the original primary or metastasis from metachronous disease.
ANED indicates alive no evidence of disease; AUNDS, alive with unknown disease status; AWD, alive with disease; DOD, dead of disease.
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manufacturer’s protocol. Samples were then run on an
automated sequencer ABI Prism 3130xl (Applied Bio-
systems) at a constant voltage of 13.2 kV for 20 minutes.
DNA sequences were compared with the reference se-
quence (http://www.ncbi.nlm.nih.gov) by the online pro-
gram BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Incidence Assessment
To assess the incidence of SDH-deficient renal car-
cinoma in an unselected population, the computerized
database of the Department of Anatomical Pathology
Royal North Shore Hospital, Sydney, Australia was
searched for all primary renal neoplasms resected between
1998 and 2013, with material available in archived FFPE
blocks (excluding consultation cases). Similar assessments
were made using the database of renal tumors, collected
between 2000 and 2013 in the Department of Pathology
and Laboratory Medicine of the Calgary Laboratory
Services and University of Calgary, Alberta, Canada and
for the tumors collected between 2003 and 2013 in the
renal tumor registry at the Department of Pathology,
Charles University, Pilsen, Czech Republic. The original
slides were reviewed explicitly in search of cases with
morphology considered compatible with proven cases of
SDH-deficient renal carcinoma.
Representative areas of each tumor from the Royal
North Shore Hospital cohort were also marked for tissue
microarray (TMA) construction. The TMA was con-
structed with duplicate 1-mm-thick cores of neoplastic
tissue from all available cases, and this TMA was eval-
uated by IHC for SDHB.
RESULTS
Clinical Features
We identified 21 previously unreported SDH-defi-
cient renal carcinomas from 14 patients. The clinical and
IHC features are summarized in Table 1. Briefly, the
mean age at presentation with a renal tumor was 39.8
years (range, 14 to 76 y; median 43.5 y), with a slight male
predominance (M:F=1.3:1). At presentation all tumors
with known size and stage were confined to the kidney,
with an average size of 51mm (range, 7 to 90mm). The
mean follow-up from initial presentation was 55 months
(4.6 y) with a range of 0 to 368 months (30.7 y). Three of
the 14 patients (21%) were known to have developed
metastatic disease. One of these patients died 12 months
after presentation (stage at presentation unknown). The
other 2 patients with metastasis had unbiopsied neo-
plasms in the contralateral kidney, which were identified
at the time of presentation with metastasis. One of these
patients developed liver metastasis, proven by fine-needle
aspiration, 4 months after partial nephrectomy and died
of disease 10 months after surgery. The other patient
developed vertebral metastases, confirmed by core biopsy,
362 months after nephrectomy and is alive with disease
368 months (30.7 y) after the initial presentation.
TABLE 1. (continued)
Mutation SDHB SDHA PAX8 AMACR CD10 c-KIT EMA CK7 CK20 AE1/AE3 CK8/18
1 SDHB [c.137G>A,pArg46Gln] Neg Pos Pos Neg Focal Neg Focal Neg Neg Neg Neg
2 SDHB [c.725G>A,p.Arg242His] Neg Pos Pos Pos Neg Neg Focal Neg Neg Neg Neg
3 SDHB [c.423+1G>A] Splice Neg Pos Pos Neg Pos Neg Pos Neg Neg Neg Neg
4 SDHB exon 3 deletion
Neg Pos Pos Focal Focal Neg Focal Neg Neg Neg Neg
Neg Pos Pos Neg Focal Neg Focal Neg Neg Neg Neg
Neg Pos
Neg Pos
5 SDHB [c.423+1G>A] Splice
Neg Pos Pos Pos Neg Neg Focal Neg Neg Neg Neg
Neg Pos Pos Pos Focal Neg Focal Neg Neg Pos Pos
Neg Pos Pos Pos Neg Neg Focal Neg Neg Neg Neg
6 Neg Pos Pos Pos Neg Neg Focal Neg Neg Neg Neg
7 SDHB [c.338G>A, p.Cys113Tyr] Neg Pos Pos Pos Pos Focal Focal Neg Neg Neg Neg
8 Neg Pos Pos Neg Focal Neg Focal Neg Neg Neg Neg
9 Neg Pos Pos Pos Focal Neg Focal Neg Neg Neg Neg
10 SDHB [c.423+1G>A] Splice Neg Pos Pos Pos Neg Neg Focal Neg Neg Focal Focal
11*
Neg Pos Pos Neg Focal Neg Focal Neg Neg Neg Neg
Neg Pos
Neg Pos
12* Neg Pos Focal Pos Neg Neg Pos Neg Neg Pos Pos
13 SDHB [c.749C>A, p.Thr250Lys] Neg Pos Pos Pos Focal Neg Pos Neg Neg Pos Pos
14 Neg Pos Focal Focal Focal Neg Focal Focal Neg Pos Pos
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Fifteen SDH-deficient renal carcinomas from 13
previously published patients4,12,16,17,40,42 were available
for central pathologic review (summarized in Table 2,
with updated survival data). These cases also showed a
male predisposition (M:F=2.3:1) but otherwise demon-
strated similar demographic features with mean age at
initial presentation of 33.8 years. Two of these patients
died of metastatic disease (at 12 and 30mo, respectively),
and 1 patient was alive with metastatic disease 132
months (11 y) after presentation. Three other previously
reported patients were also known to have developed
metastatic disease (2 to the adrenal gland, 1 to retro-
peritoneal lymph node) but lacked further follow-up.
When both the previously reported (Table 2) and
novel patients (Table 1) were combined, the mean age at
first presentation was 37 years (range, 14 to 76 y). There
was a slight male predominance (M:F=1.7:1). There
were 4 patients with multifocal tumors in the same kid-
ney, and bilateral neoplasms were present in 7 of 27
(26%) patients.
The incidence of synchronous or metachronous
GIST and pheochromocytoma/paraganglioma as well as
the family history of renal carcinoma, GIST, and pheo-
chromocytoma/paraganglioma are presented in Table 3.
Briefly, 4 of 27 (15%) patients also had SDH-deficient
GISTs, and 4 of 27 (15%) patients developed para-
gangliomas. Five patients (19%) had first-degree relatives
with renal carcinoma and 1 patient a second-degree rel-
ative. There were 5 first-degree and 2 second-degree rel-
atives with pheochromocytoma/paraganglioma and 1
first-degree relative with SDH-deficient GIST. Two pa-
tients also had incidental small renal angiomyolipomas
resected. The angiomyolipoma from patient 6 was 10mm
in diameter, and the angiomyolipoma from patient 9 was
3mm in diameter. The angiomyolipoma from patient 9
was available for IHC and demonstrated positive staining
for SDHB. Neither patient with angiomyolipomas was
known to have tuberous sclerosis complex.
Pathologic Features
Centralized pathologic review was undertaken on 36
available SDH-deficient renal carcinomas from 27 pa-
tients. Macroscopic descriptions of the tumors were not
always detailed or available, but in all cases with gross
description, the tumors were characterized as well cir-
cumscribed with a tan to red cut surface. Some of the
tumors were noted to demonstrate cystic change. Al-
though this cystic change was sometimes striking
(Fig. 1A), this was not a constant feature, and the ma-
jority of tumors were solid (Fig. 1B).
Histologically, the dominant morphology was as
previously described4 and was found at least focally in 34
tumors from 24 patients. This morphology is illustrated
in Figures 2–5, and whole-slide scanned images from all
tumors are available for review at http://www.cancer
dxpathology.org.au. Briefly, the tumors were well cir-
cumscribed or demonstrated coarse lobulation, with a
pushing border sometimes associated with a pseudocap-
sule (Figs. 2A, B). Cystic change in the form of microcysts
and macrocysts was commonly appreciated histologically,
and these cysts usually contained pale eosinophilic fluid
(Figs. 2C, D). In a few tumors the stroma showed areas of
prominent myxoid change or hyalinization. The neo-
plastic cells were cuboidal to oval with round nuclei and
inconspicuous nucleoli, consistent with an ISUP nucleo-
lar (nuclear) grade 2 in 26 cases (Fig. 3). The nuclei were
grade 3 in 7 cases and grade 4 in 3 cases (all of
which demonstrated at least focal sarcomatoid change).
TABLE 2. Clinical, Molecular, and IHC Details of Previously Published Patients With Material Available for Pathologic Review
Prev. Pub. Location Age Sex
Size
(mm) Surgery Stage
ISUP
Grade Necrosis
Follow-up
(mo) Status
15 16 Bilateral 27 M 41 Biopsy of
met only
Stage 4 3 Yes 30 DOD
16 4,12 Right 21 F 22 Wedge 1 (T1ANO) 2 No 84 ANED
17 4,12 Left 28 M 29 Nephrectomy 1 (T1A) 2 No 48 ANED
18 4,12 Left 22 M 100 Nephrectomy Stage 4 4 Yes 12 DOD
19 4,37,42 Left 58 F 78 Nephrectomy 2 (T2AN0) 2 No 24 ANED
20 17 Right 22 F 65 Nephrectomy 1 (T1BN0) 2 No 160 ANED
21 41 M Nephrectomy No
Left 25 90 Nephrectomy 2 (T2AN0) 2 No 72 ANED
Left 25 28 Nephrectomy 1 (T1AN0) 3 No 72 ANED
Right 31 13 Radio-
frequency
ablation
1 (T1AN0) 2 No 0 ANED
22 41 Right 23 M 25 Nephrectomy 1 (T1AN0) 2 No 60 ANED
23 41 Left 36 M 130 Nephrectomy 2 (T2BN0) 3 No 132 AWD Spleen met 66mo,
liver met 10mo
24 43 40 M 4 3 No Adrenal metastasis
25 43 35 M 3 Yes Retroperitoneal node
metastasis
26 43 44 M 4 3 No Adrenal metastasis
27 43 Right 59 F 70 2 (T2AN0) 2 No AUNDS
ANED indicates alive with no evidence of disease; AUNDS, alive with unknown disease status; AWD, alive with disease; DOD, dead of disease.
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In most tumors the nuclear chromatin commonly had a
dispersed quality reminiscent of cells with neuroendocrine
differentiation. The cell borders were sometimes indis-
tinct. The cytoplasm was eosinophilic or flocculent but
not truly oncocytic (Fig. 3). Tumor cells demonstrated a
variably solid or nested architecture, and sometimes nests
of tumor cells surrounded cystic spaces imparting a
pseudoglandular appearance.
The most constant and distinctive histologic feature
was the presence of cytoplasmic vacuoles and inclusion-
like spaces (Figs. 3C, D). These contained either pale
eosinophilic fluid or flocculent material. In most cases,
these inclusions were readily identified throughout the
tumor, but in some cases, particularly in those with
higher-grade nuclei, these cytoplasmic inclusions were
subtle and were only identified focally after a thorough
search of multiple sections (Fig. 5). Non-neoplastic tu-
bules or glomeruli were frequently entrapped at the pe-
riphery of the neoplasm (Fig. 4). Intratumoral mast cells
were commonly highlighted with c-KIT IHC but were not
appreciable as a conspicuous finding on routine hema-
toxylin and eosin sections. Allowing for the secondary
effects of the tumor, the adjacent non-neoplastic kidney
was normal, and no dysplastic or precursor lesions were
identified in the adjacent renal parenchyma.
In the 5 tumors with ISUP nucleolar (nuclear) grade
3 nuclei, which were still recognizable as SDH-deficient
renal carcinomas, in addition to prominent nucleoli, the
neoplastic cells in the higher-grade areas acquired darker
and coarser chromatin and more dense eosinophilic
(rather than flocculent) cytoplasm. The nuclei in these
areas were about 2 times larger than the nuclei in low-
grade areas and demonstrated oval to slightly elongated
shape, with irregular nuclear outlines. In some areas these
tumors lost their nested architecture and commonly grew
as solid sheets, occasionally with a very focal abortive
papillary architecture.
Three cases demonstrated frank sarcomatoid
transformation, with ISUP nucleolar (nuclear) grade 4.
The sarcomatoid areas were composed of pleomorphic
spindled cells essentially indistinguishable from other
high-grade sarcomatoid renal carcinomas. In 2 of the
cases with sarcomatoid change, the sarcomatoid areas
were in direct continuity with areas showing the stereo-
typical low-grade morphology (including ISUP nucleolar
[nuclear] grade 2 nuclei), indicating true dedifferentiation
rather than the existence of a different tumor type. In the
other case with areas of sarcomatoid transformation, the
entire tumor was high grade (either grade 3 or grade 4
nuclei). However, even in this case intracytoplasmic in-
clusions, albeit subtle, were identified after a search of
multiple slides.
Although fibrosis, hyalinization, and hemorrhage
were not uncommon, true coagulative necrosis was only
found in 4 tumors—all ISUP nucleolar (nuclear) grade
3 or 4.
Only 2 of 36 (6%) cases lacked any areas with
typical morphologic features or cytoplasmic inclusions
and would not have been recognizable as SDH-deficient
renal carcinomas on the basis of morphology. These
cases, illustrated in Figure 6, were previously reported by
Miettinen et al42 and identified by screening a large cohort
by IHC rather than triaging IHC on the basis of mor-
phology.42 In 1 case, the morphology was that of a typical
clear cell renal carcinoma, ISUP nucleolar (nuclear) grade
3. In this case, only 1 block was available for review. In
the second case, the morphology was in keeping with
papillary renal carcinoma type 2, ISUP nucleolar (nu-
clear) grade 3. In this case, 4 blocks were available for
review, all of which demonstrated similar histology.
Immunohistochemistry
All cases demonstrated negative staining for SDHB
in all neoplastic cells (which was considered an inclusion
criterion for the study). All cases also showed preserved
positive staining for SDHA. At least focal positive
staining for PAX8 was found in all cases. All but 1 case
(96%) demonstrated at least focal reactivity for EMA,
TABLE 2. (continued)
Germline Mutation SDHB SDHA PAX8 AMACR CD10 c-KIT EMA CK7 CK20 AE1/AE3 CK8/18
15 SDHB c.88delC Neg Pos Pos Neg Focal Neg Pos Focal Neg Pos Pos
16 SDHB c.268C>T Neg Pos Pos Neg Neg Neg Focal Neg Neg Neg Neg
17 SDHB c.166-170 delCCTCA Neg Pos Pos Pos Focal Neg Focal Neg Neg Focal Neg
18 SDHB c.423+1G>A Neg Pos Pos Focal Focal Neg Pos Pos Neg Pos Pos
19 SDHB c.72+1G>T Neg Pos Pos Pos Focal Neg Neg Neg Neg Neg Neg
20 SDHC c.380A>G Neg Pos Pos Neg Neg Neg Focal Neg Neg Neg Neg
21 SDHB c.3G>A
Neg Pos
Neg Pos
Neg Pos
22 SDHB c.3G>A Neg Pos Pos Pos Focal Neg Focal Neg Neg Neg Neg
23 SDHB exon 3 deletion Neg Pos Pos Pos Focal Neg Focal Neg Neg Neg Neg
24 Neg Pos
25 Neg Pos
26 Neg Pos
27 Neg Pos
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which was often quite limited, in some cases involving
<1% of neoplastic cells, and commonly restricted to the
apical border of cells. Only 3 of 25 cases (12%) demon-
strated positive staining for CK7, and this staining was
focal in 2 cases. Immunoreactivity for other markers was
not specific. It is noteworthy that 68% of the cases
demonstrated completely negative staining for all cyto-
keratins. IHC for c-KIT was negative in 96% of cases but
did highlight scattered intratumor mast cells in many
tumors.
Genetic Testing
Of the previously reported cases, 9 had undergone
germline molecular testing and were found to harbor a
pathogenic mutation in SDHB (8 cases) or SDHC
(1 case)—mutation data previously reported.4,8,12,16,17,40
Of the previously unpublished cases, genetic testing was
performed for SDHB in 8 patients, and in all of them a
pathogenic germline mutation was identified. That is all
17 patients with SDH-deficient renal carcinoma who have
undergone testing were found to harbor a germline mu-
tation of 1 of the components of the mitochondrial
complex 2 (16 SDHB, 1 SDHC, and none in SDHA or
SDHD).
Morphologic Predictors of Metastasis
A total of 9 patients with pathologic material
available for histologic review developed metastatic dis-
ease (6 previously reported and 3 new patients). Four of
these patients died of metastatic disease at a mean of 18
months after initial presentation, all of whom had an IS-
UP nucleolar (nuclear) grade of 3 or 4 at presentation, and
3 of whom had coagulative necrosis. The other patient
with coagulative necrosis was known to have metastatic
disease but had no further follow-up information avail-
able. Two patients were alive with metastatic disease, 132
TABLE 3. Personal and Family History of Renal Carcinoma, SDH-deficient GIST, Pheochromocytoma, Paraganglioma
Total
Number of
RCCs
Family
History
RCC
Personal History
SDH-deficient GIST
Family History
SDH-deficient GIST
Personal History
Pheochromocytoma or
Paraganglioma
Family History
Pheochromocytoma or
Paraganglioma
1 1 No No No No No
2 1 Unknown Unknown Unknown Unknown Unknown
3 1 No No No No No
4 4 No No No No No
5 3 No Age 45 y No No No
6 1 No No No No No
7 1 No No No No No
8 1 Unknown No Unknown No Unknown
9 1 No No No No No
10 2* No No No No Nephew, paraganglioma age
23 y
11 3 Son of
patient 12
No No Paraganglioma, age 14 y No
12 2 Mother of
patient 11
Unknown Unknown Unknown Mother of patient 11
13 2* No No Unknown No Unknown
14 1 No Age 54 y No No No
15 2w No No No No No
16 1 No No No No Mother, paragangliomas3
(age 43, 45, 45 y)
17 1 Maternal
aunt, age 34 y
No No Paraganglioma age 28 y No
18 1 No No Brother age 44 y No Nephew, paraganglioma age
19 y
Brother, paraganglioma age 44 y
19 1 Sister Renal
Carcinoma
No No No Daughter metastatic
pheochromocytoma
20 1 No Age 12 and 33 y No No No
21 3 Brother of
patient 22
No No Paraganglioma, age 25 y No
22 1 Brother of
patient 21
No No No Brother of patient 21
23 1 No No No Paraganglioma age 30 y
Paraganglioma age 34 y
No
24 1 Unknown Unknown Unknown Unknown Unknown
25 1 Unknown Unknown Unknown Unknown Unknown
26 1 Unknown Unknown Unknown Unknown Unknown
27 1 Unknown Age 19 Unknown Unknown Unknown
*This number includes a presumed SDH-deficient renal carcinoma identified by imaging in the contralateral kidney but not biopsied or resected.
wThis number includes bilateral renal tumors identified on imaging but not biopsied or resected.
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FIGURE 1. Although many of the tumors demonstrated cystic change, which was often profound (A, 85mm tumor from the right
kidney of patient 9), this was not a constant finding, and some neoplasms were solid (B, 2 solid tumors, 90 and 28mm, from the
left kidney of patient 21).
FIGURE 2. The tumors were well circumscribed (A) and only occasionally separated from the adjacent kidney by a pseudocapsule
(B). C and D, Cystic change was commonly appreciated histologically, and the cystic spaces contained pale eosinophilic fluid
(hematoxylin and eosin).
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months (11 y) and 368 months (30.7 y) after initial pre-
sentation. One of these 2 patients showed increased
cytologic atypia and an ISUP nucleolar (nuclear) grade 3
but lacked frank sarcomatoid change and subsequently
developed biopsy-proven metastases in the spleen at 66
months (5.5 y) and the liver at 108 months (9 y) after initial
presentation. The other patient showed only typical low-
grade features in the initial resection with an ISUP nu-
cleolar (nuclear) grade of 2, but then developed biopsy-
proven vertebral metastasis 30 years later. The metastasis
showed increased cytologic atypia with an ISUP nucleolar
(nuclear) grade 3 and an abortive papillary architecture
but lacked sarcomatoid differentiation (Fig. 7). Im-
portantly, at the time of diagnosis of the metastasis, this
patient was found to have a solid tumor on diagnostic
imaging in her contralateral kidney. Unfortunately, this
tumor was not biopsied or resected, and the origin of the
metastasis, either from the original SDHB tumor or from
the metachronous neoplasm in the contralateral kidney,
could not be established with certainty. Both patients with
exclusively variant morphology (illustrated in Fig. 6) de-
veloped metastatic disease, but no further follow-up in-
formation was available.
Estimated Incidence
The review of consecutive unselected cases from the
Department of Anatomical Pathology, Royal North
Shore Hospital, Sydney, Australia identified 420 renal
neoplasms. None of these tumors demonstrated mor-
phologic features of SDH-deficient renal carcinoma, and
IHC for SDHB, performed on a TMA, was positive in all
cases, suggesting that the incidence in a truly unselected
group of primary renal carcinomas is <1 in 420 (0.2%).
The database from the Rockyview Hospital (Calgary
Laboratory Services and University of Calgary) included
1750 in-house resected renal tumors. All renal neoplasms,
reported as “unclassified” or “oncocytic” were reviewed,
and 2 cases were identified on the basis of morphology,
FIGURE 3. The tumor cells had eosinophilic cytoplasm but lacked the granularity associated with true oncocytes. In some cases
the eosinophilic cytoplasm was dense (A), but in most cases (B and C) it had a pale and wispy, almost flocculent, appearance. In
some tumors (D) the combinations of flocculent cytoplasm and frequent intracytoplasmic inclusions imparted a bubbly ap-
pearance to many of the tumor cells (hematoxylin and eosin).
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with an estimated overall incidence of 0.1%. The mor-
phologic review of the renal tumor registry at the
Department of Pathology, Charles University, Pilsen,
Czech Republic, identified only 1 case from 2004 locally
resected tumors, with an estimated incidence of 0.05%.
DISCUSSION
SDH-deficient renal carcinoma has recently been
accepted as a provisional entity in the 2013 ISUP
Vancouver Classification. However, reflecting its rarity,
published experience with this tumor has been limited. To
substantiate its distinctive morphologic and clinical fea-
tures, the prognosis, and the genetic associations of SDH-
deficient renal carcinoma and to estimate its incidence, we
evaluated a multi-institutional cohort of 36 SDH-deficient
renal carcinomas from 27 patients, including 21 pre-
viously unreported cases.
This study confirmed that the previously reported
distinctive morphologic features of SDH-deficient renal
FIGURE 4. Serial sections stained with hematoxylin and eosin (A and C) and SDHB IHC (B and D). Frequently entrapped benign
tubules were noted at the edge of the tumors. SDHB IHC demonstrates positive staining in the internal controls (including the
entrapped benign tubules) but all the neoplastic cells are negative.
FIGURE 5. In this case with higher-grade nuclear features and
early dedifferentiation, the intracytoplasmic inclusions are
more subtle (arrows) and were identified only after a careful
search (hematoxylin and eosin).
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carcinoma are highly specific for the diagnosis. That is, all
the cases with the typical morphology demonstrated
negative staining for SDHB. Therefore morphology
should be considered the primary screening test to iden-
tify SDH-deficient renal carcinoma in routine practice.
However, we caution that the study was not intended or
designed to demonstrate that all renal carcinomas arising
in the context of SDH mutation will show this mor-
phology. That is many cases reported in this series were
first identified primarily on the basis of morphology, and
only selected cases with compatible morphology then
underwent screening IHC. Therefore, there may be a se-
lection bias in this series toward cases with typical mor-
phologic features. It is therefore worth noting that 2 (6%)
cases from this series (both identified by IHC screening of
large cohorts) lacked this distinctive morphology, and in
other cases (particularly those with high ISUP nuclear
[nucleolar] grade) this morphology was only a focal
finding and may not be appreciated in routine clinical
practice. Therefore, in addition to performing SDHB
IHC on cases with compatible morphology, regardless of
age or clinical features, we would also recommend that
screening IHC be considered for other cases with sug-
gestive clinical features (for example, multifocality, onset
at a young age, or a personal or family history of renal
carcinoma, pheochromocytoma/paraganglioma, gastric
GIST, or pituitary adenoma).
We would estimate the true incidence of SDH-de-
ficient renal carcinoma as being 0.05% to 0.2% of un-
selected renal neoplasms. In the local case series from
Australia (Sydney), we found no morphologically or im-
munohistochemically compatible cases in 420 consecutive
unselected renal tumors screened both by morphology
and IHC. Similarly, only 1 and 2 cases were identified in
large population-based cohorts of 2004 and 1750 con-
secutive renal carcinomas, respectively, in institutions
from Europe (Pilsen) and North America (Calgary),
which were screened by morphology. A limiting factor in
the 2 latter series was the lack of systematic IHC for
SDHB and SDHA, which could have potentially detected
additional cases, particularly any with variant morphol-
ogy. However, identification of the cases in these cohorts
FIGURE 6. Cases with variant morphology. One case demonstrated morphology reminiscent of conventional clear cell renal
carcinoma of ISUP nucleolar (nuclear) grade 3 (A and B). C and D, A second case demonstrated a papillary architecture with
prominent nucleoli, reminiscent of type 2 papillary renal carcinoma (hematoxylin and eosin).
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was based on the recognition of an unusual morphology
and routine IHC, in the setting of large centralized
uropathology practices with experienced genitourinary
pathologists. Thus the estimated incidence derived from 3
institutions from different continents was similar and
ranged from 0.05% to 0.2%. These results are also in
keeping with the recently reported data by Miettinen
et al,42 who performed IHC on 711 renal carcinomas and
64 oncocytomas and found that only 4 cases (0.5%)
demonstrated loss of staining for SDHB.
The low incidence of SDH deficiency in renal car-
cinomas is similar to the low incidence reported in pitui-
tary adenomas (0.3%),15 and contrasts to the high
incidence found in pheochromocytoma/paraganglioma
(3% in adrenal pheochromocytomas and up to 40% in
extra-adrenal parangangliomas)6 and significant in-
cidence in gastric GIST (5% to 7.5%).3,10 Therefore,
although it has been recommended that all pheochro-
mocytomas and all paragangliomas as well as gastric
GISTs with compatible morphology for SDH-deficient
GIST undergo screening IHC for SDHB,1,6,18 it is un-
likely to be cost-effective or practical to screen all renal
carcinomas with SDHB IHC.
This study confirmed that classical low-grade tumors
showing typical histologic features and an ISUP nucleolar
(nuclear) grade 2 are usually cured by excision alone. Of
the 9 patients who developed metastatic disease, in only 2
did the primary tumor demonstrate exclusively low-grade
features with an ISUP nucleolar (nuclear) grade 2. Im-
portantly, by the time of metastasis, both of these patients
had developed a contralateral renal neoplasm, which had
not been resected or biopsied. Therefore the metastasis
may have arisen from the metachronous tumors, which
may have been of higher grade and not from the primary
low-grade SDH-deficient renal tumor.
We note that SDH-deficient renal carcinoma may
undergo dedifferentiation including sarcomatoid trans-
formation, and cases with high-grade nuclei commonly
FIGURE 7. Representative photomicrographs from the primary tumor (A and B) and the vertebral metastasis (C and D) of case 10.
The primary tumor demonstrated stereotypical low-grade features with ISUP nucleolar (nuclear) grade 2. In the metastasis
documented 30 years later, the tumor demonstrated high-grade nuclear features but still showed negative staining for SDHB. As
the patient had a contralateral renal tumor, which was unbiopsied at the time of metastatic disease, this may represent spread
from a second primary tumor (hematoxylin and eosin).
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metastasize. In fact, metastatic disease developed in 7 of
10 patients with ISUP nucleolar (nuclear) grade 3 or 4
nuclei or variant morphology. Although hemorrhage,
fibrosis, and hyalinization were relatively common, only 4
tumors demonstrated true coagulative necrosis. Given
that all 4 of these metastasized (and 3 were confirmed
dead of disease), it is likely that coagulative necrosis is an
adverse prognostic indicator.
Given the low risk for metastatic disease and the
high incidence of bilateral tumors in 7 of 27 (26%) pa-
tients, our findings support nephron-sparing surgery for
patients with low-grade tumors. Although there is in-
sufficient evidence to recommend adjuvant treatment,
patients with high-grade neoplasms (variant morphology,
sarcomatoid change, coagulative necrosis, or high ISUP
nucleolar [nuclear] grade) should be considered at high
risk for metastasis, and consideration should be given to
more radical treatments in these patients. We note that in
2 patients metastasis occurred >5 years after the initial
presentation, and therefore extended (if not lifelong)
follow-up is required for late recurrences, as well as
metachronous disease and other syndromic manifes-
tations of germline SDH mutation (GIST, para-
ganglioma, pituitary adenoma).1
The differential diagnosis of SDH-deficient renal
carcinoma, which includes oncocytoma and chromo-
phobe renal carcinoma is limited, and we consider loss of
staining for SDHB as definitive confirmation of the di-
agnosis. Although SDHB IHC is not widely available, the
morphologic features of typical SDH-deficient renal car-
cinoma, such as uniform low-grade morphology in the
great majority of cases, flocculent (rather than truly on-
cocytic) cytoplasm, cytoplasmic vacuoles, lack of distinct
cell borders, negative staining for c-KIT, and commonly
negative or focal cytokeratin reactivity, are important
clues to the diagnosis.
In our series of SDH-deficient renal carcinomas,
germline mutations were identified in all 17 patients who
underwent genetic testing. This is similar to the findings in
SDH-deficient paragangliomas and pituitary adenomas,
where the presence of negative staining for SDHB almost
always signifies germline mutation of one of the components
of the mitochondrial complex 2 (SDHA, SDHB, SDHC,
SDHD, SDHAF2), rather than being due solely to somatic
inactivation.1 In fact, we are aware of only 2 cases of SDH-
deficient paraganglioma and 1 case of SDH-deficient pitui-
tary adenoma in which double-hit SDH inactivation has
occurred in the absence of germline mutation.15,44,45 It is
possible that our series is subject to a referral bias because
patients with known mutation or personal or family histories
of syndrome-related tumors were more likely to be recog-
nized and included in this study. However, our findings
suggest that, similar to paraganglioma and pituitary ad-
enoma, it is likely that most, perhaps almost all, SDH-defi-
cient renal carcinomas will be associated with germline
mutation of one of the SDH genes. Therefore, the diagnosis
of SDH-deficient renal carcinoma can be considered an ab-
solute indication for germline SDH mutation testing. No
clear-cut genotype-phenotype correlations have emerged,
although it is interesting to note in this series that 4 unrelated
patients who developed renal carcinoma all harbored the
same SDHB [c.423+1G>A] splice site mutation and that 2
of the patients with this mutation developed multifocal dis-
ease.
Although SDH-deficient renal carcinoma shows an
extremely strong correlation with germline SDH muta-
tion, we believe that IHC remains a phenotype test rather
than a genotype test, and it is likely that not all SDHB
IHC–negative tumors will be shown to have SDH muta-
tions using current technology. Therefore, as we have
previously stated in the setting of paraganglioma,6 we do
not believe that specialized consent or formal genetic
counseling would ordinarily be required before IHC is
performed. This is analogous to IHC for DNA mismatch-
repair proteins being used to triage patients with color-
ectal cancer for genetic testing for Lynch syndrome
wherein there is now a trend toward universal screening,
and most jurisdictions do not require genetic counseling
before screening IHC is performed.
To date, no mutations in SDHA have been reported
in association with renal carcinoma, but given that loss
of staining for SDHA identifies both paragangliomas
and GISTs associated with germline SDHA muta-
tion,1,18–20,46–48 we would recommend that IHC for
SDHA also be performed in SDH-deficient renal carci-
noma to assist in triaging genetic testing for SDHA
mutation.
The extremely high rate of germline mutation in the
SDH subunits in SDH renal carcinoma is different to that
found in SDH-deficient GIST, in which approximately
30% of cases are associated with SDHA mutation, and
10% to 20% of cases are associated with mutations in the
other SDH subunits (SDHB, SDHC, or SDHD), leaving
the mechanism of SDH deficiency uncertain in up to half
of cases.18,19,46–48 It is noteworthy that some patients with
SDH-deficient GIST but without germline mutation were
found to have the Carney Triad (the nonhereditary but
syndromic association of SDH-deficient GIST, para-
ganglioma, and pulmonary chondroma).3 It is therefore
possible that some patients with SDH-deficient renal
carcinoma may be syndromic, even if no germline muta-
tions are identified. From a practical point, because long-
term follow-up is required due to the possibility of late
metastasis, we would also recommend long-term follow-
up for other syndromic manifestations (pheochromocy-
toma/paraganglioma, GIST, pulmonary chondroma, or
pituitary adenoma), regardless of whether or not a
germline mutation is identified. In fact, although there
may have been a selection bias toward recognizing pa-
tients with syndromic disease, we note that in our series
30% of patients also developed either paraganglioma or
SDH-deficient GISTs—a particularly striking association
given the relative rarity of these tumors.
In conclusion, SDH-deficient renal carcinoma rep-
resents a distinct and rare renal neoplasm, which is defined
by loss of IHC staining for SDHB. Because of its rarity, it
is impractical to perform reflex screening IHC on all renal
cancers. However, the great majority of SDH-deficient
Gill et al Am J Surg Pathol  Volume 38, Number 12, December 2014
1600 | www.ajsp.com r 2014 Lippincott Williams & Wilkins
renal tumors (94% in this series) demonstrated typical
appearances at least focally and were recognized by their
uniform low-grade cytology, cytoplasmic vacuoles, eosi-
nophilic or flocculent (rather than truly oncocytic) cyto-
plasm, focal cystic change, and solid to lobulated growth
with peripherally entrapped renal tubules. In tumors ex-
hibiting low-grade nuclear features with ISUP nucleolar
(nuclear) grade 2, metastasis is unusual but can occur even
after a prolonged period. SDH-deficient renal carcinoma
may be associated with high ISUP nucleolar (nuclear)
grade, coagulative necrosis or sarcomatoid trans-
formation, in which case the development of metastatic
disease is much more likely. SDH-deficient renal carci-
nomas are commonly multifocal and with prolonged fol-
low-up, bilateral tumors can be identified in up to 26% of
patients. To date, all reported cases have been associated
with germline mutations of the SDH genes.
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